Clovis Oncology

Last updated

Clovis Oncology
Company type Public
Nasdaq:  CLVS
Russell 2000 Component
Industry Pharmaceutical
FoundedApril 2009;15 years ago (2009-04) in Boulder, Colorado
FounderPatrick Mahaffy
Headquarters
Boulder, Colorado
,
U.S.
RevenueIncrease2.svg $165 Million(2020)
Number of employees
429

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. [1] Clovis was founded in 2009 and is headquartered in Boulder, Colorado. [2] The company is a publicly traded company on NASDAQ under the symbol CLVS [3] and is in the NASDAQ Biotechnology Index [4] with several products in its product pipeline. [5] As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. [6] In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy. [7]

Contents

History

Clovis Oncology was founded in 2009 by Patrick Mahaffy in Boulder, Colorado. The company was named in honor of the Mahaffy cache, a collection of Clovis period stone tools dated to 11,000 BCE, discovered in the front yard of Mahaffy's home in Boulder. [8]

Product development

Rociletinib

The company was developing rociletinib, [9] as a treatment for non-small cell lung cancer. [1] [10] [11] [12] A phase III trial was completed in April 2016 [13] and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib). [13] According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment. [14]

In September 2018, the company and two former executives agreed to a $20 million settlement with the Securities and Exchange Commission on claims it exaggerated to investors the efficacy of Roci in patient trials. [15] [16]

Rucaparib

Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer. [17] In December 2016, the Food and Drug Administration granted an accelerated approval for the use of rucaparib "for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies". [18] In 2023, rucaparib was sold to Pharmaand GmbH (Pharma&) as part of Clovis's bankruptcy proceedings. [19]

Lucitanib

Lucitanib is a VEGFR inhibitor. [20] It is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors. [21]

Related Research Articles

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

<span class="mw-page-title-main">Cediranib</span> Chemical compound

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

<span class="mw-page-title-main">Lestaurtinib</span> Chemical compound

Lestaurtinib is a tyrosine kinase inhibitor structurally related to staurosporine. This semisynthetic derivative of the indolocarbazole K252a was investigated by Cephalon as a treatment for various types of cancer. It is an inhibitor of the kinases fms-like tyrosine kinase 3 (FLT3), Janus kinase 2 (JAK2), tropomyosin receptor kinase (trk) A (TrkA), TrkB and TrkC.

<span class="mw-page-title-main">ARIAD Pharmaceuticals</span> Defunct oncology company

ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of Takeda Oncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered in Cambridge, Massachusetts. ARIAD engaged in the discovery, development, and commercialization of medicines for cancer patients.

<span class="mw-page-title-main">Olaparib</span> Chemical compound (cancer therapy drug)

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.

<span class="mw-page-title-main">PARP inhibitor</span> Pharmacological enzyme inhibitors of poly (ADP-ribose) polymerases

PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).

<span class="mw-page-title-main">Rucaparib</span> Chemical compound

Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth.

<span class="mw-page-title-main">Tivozanib</span> Medication

Tivozanib, sold under the brand name Fotivda, is a medication used for the treatment of advanced renal cell carcinoma. It is an oral VEGF receptor tyrosine kinase inhibitor.

<span class="mw-page-title-main">Nintedanib</span> Chemical compound

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

<span class="mw-page-title-main">Compugen Ltd.</span> Israeli biotechnology company

CompugenLtd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

<span class="mw-page-title-main">Binimetinib</span> Chemical compound

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers. In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, it was approved by the FDA for treatment of NSCLC with a BRAF V600E mutation in combination with encorafenib. It was developed by Array Biopharma.

<span class="mw-page-title-main">Atezolizumab</span> Monoclonal anti-PD-L1 antibody

Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).

<span class="mw-page-title-main">Triciribine</span> Chemical compound

Triciribine is a cancer drug which was first synthesized in the 1970s and studied clinically in the 1980s and 1990s without success. Following the discovery in the early 2000s that the drug would be effective against tumours with hyperactivated Akt, it is now again under consideration in a variety of cancers. As PTX-200, the drug is currently in two early stage clinical trials in breast cancer and ovarian cancer being conducted by the small molecule drug development company Prescient Therapeutics.

<span class="mw-page-title-main">Talazoparib</span> Chemical compound

Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostate cancer. It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib.

<span class="mw-page-title-main">Niraparib</span> Anti-cancer medication

Niraparib, sold under the brand name Zejula, is an anti-cancer medication used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is taken by mouth. It is a PARP inhibitor.

<span class="mw-page-title-main">Capmatinib</span> Chemical compound

Capmatinib, sold under the brand name Tabrecta, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.

Verastem, Inc., doing business as Verastem Oncology, is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index.

Elizabeth Ruth Plummer is a Professor of Experimental Cancer Medicine at Newcastle University and an oncologist specialising in treating patients with melanoma. Based in Newcastle, she directs the Sir Bobby Robson Cancer Trials Research Centre, set up by the Sir Bobby Robson Foundation to run early-stage clinical trials.v Plummer and the Newcastle team won a 2010 Translational Cancer Research Prize from Cancer Research UK for work using rucaparib to treat ovarian cancer. Plummer was elected as a fellow of the UK's Academy of Medical Sciences in 2018.

Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.

<span class="mw-page-title-main">G1 Therapeutics</span> Pharmaceutical company

G1 Therapeutics, Inc. is an American biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company specializes in developing and commercializing small molecule therapeutics for the treatment of patients with cancer.

References

  1. 1 2 "Clovis Oncology: A Winning Or Losing Lottery Ticket?". Forbes. November 16, 2015. Retrieved January 4, 2016.
  2. ↑ "CLVS Profile". finance.yahoo.com.
  3. ↑ "Clovis Oncology Inc". www.marketwatch.com. Retrieved January 4, 2016.
  4. ↑ "Overview NBI". nasdaq.com. Retrieved January 4, 2016.
  5. ↑ "Clovis Oncology – Products & Companion Diagnostics". Clovisoncology.com. March 9, 2015. Archived from the original on March 9, 2015. Retrieved January 4, 2016.
  6. ↑ Clovis Oncology, Inc. Form 10-K for the fiscal year ended December 31, 2017.
  7. ↑ Singh, Vandana (December 12, 2022). "Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286". yahoo.com. Retrieved December 12, 2022.
  8. ↑ "13,000-year-old stone tool cache set for exhibit at CU-Boulder". The Chaffee County Times. October 9, 2015. Archived from the original on July 22, 2021. Retrieved July 22, 2021.
  9. ↑ "A Festivus for the Invest in Us -- It's Time for the Airing of Grievances | Fox Business". Fox Business . March 7, 2016. Archived from the original on March 7, 2016. Retrieved March 15, 2021.
  10. ↑ Wallace, Alicia (November 16, 2015). "Clovis Oncology stock bludgeoned after delay in cancer drug approval". www.denverpost.com. Retrieved January 4, 2016.
  11. ↑ "Clovis Oncology Announces Regulatory Update for Rociletinib NDA Filing". www.reuters.com. Archived from the original on March 5, 2016. Retrieved January 4, 2016.
  12. ↑ "FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC". OncLive. November 16, 2015. Retrieved January 4, 2016.
  13. 1 2 Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%. April 2016
  14. ↑ "About Clovis" . Retrieved November 18, 2016.
  15. ↑ "Clovis Oncology, execs to pay $20 million to settle SEC charges". Reuters. September 18, 2018. Retrieved September 28, 2018.
  16. ↑ "Clovis, CEO, Ex-CFO Agree to Pay $20M+ to Settle SEC Charges | GEN". GEN. September 19, 2018. Retrieved September 28, 2018.
  17. ↑ "Rucaparib at Clovis". Archived from the original on April 13, 2016. Retrieved April 5, 2016.
  18. ↑ Balasubramaniam, Sanjeeve; Beaver, Julia A.; Horton, Sara; Fernandes, Laura L.; Tang, Shenghui; Horne, Hisani N.; Liu, Jinzhong; Liu, Chao; Schrieber, Sarah J.; Yu, Jingyu; Song, Pengfei (December 1, 2017). "FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer". Clinical Cancer Research. 23 (23): 7165–7170. doi: 10.1158/1078-0432.CCR-17-1337 . ISSN   1557-3265. PMID   28751443.
  19. ↑ Bell, Jacob (April 7, 2023). "Navigating bankruptcy, Clovis reaches deal to sell cancer drug Rubraca". BioPharma Dive. Retrieved October 4, 2023.
  20. ↑ "Lucitanib at Clovis". Archived from the original on April 14, 2016. Retrieved April 5, 2016.
  21. ↑ Soria; et al. (2014). "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors". Annals of Oncology. 25 (11): 2244–51. doi: 10.1093/annonc/mdu390 . PMID   25193991.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.